Page 838 - Read Online

Page 12 of 18 Franco et al. Hepatoma Res 2018;4:74 I http://dx.doi.org/10.20517/2394-5079.2018.94

15. Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected
with HIV-1. N Engl J Med 2015;373:714-25.
16. Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-
8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet
HIV 2015;2:e319-27.
17. Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected
with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION-2 study. Clin Infect Dis 2018;67:1010-7.
18. Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, et al. Virologic response following combined ledipasvir and sofosbuvir
administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015;313:1232-9.
19. Naggie S, Cooper C, Saag M, Workowski K, Ruane P, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N
Engl J Med 2015;373:705-13.
20. Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin
for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015;313:1223-31.
21. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, et al. Simeprevir plus sofosbuvir, with or without ribavirin,
to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive
patients: the COSMOS randomised study. Lancet 2014;384:1756-65.
22. AASLD/IDSA. Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1: the phase
3 ASTRAL-5 study abstract PS104. Available from: https://www.hcvguidelines.org/references/wyles-2016. [Last accessed on 28 Nov
2018]
23. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV
infection in patients with advanced liver disease. Gastroenterology 2015;149:649-59.
24. Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype
1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis
2016;16:685-97.
25. Bourlière M, Bronowicki JP, de Ledinghen V, Hézode C, Zoulim F, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat
patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-
blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015;15:397-404.
26. Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated
cirrhosis. N Engl J Med 2015;373:2618-28.
27. Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection.
N Engl J Med 2015;373:2599-607.
28. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus
infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 2016;63:1493-505.
29. Reau N, Kwo PY, Rhee S, Brown RS Jr, Agarwal K, et al. MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or
renal transplant adults with chronic hepatitis C genotype 1-6 infection. Hepatology 2017;66:S90-1.
30. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV
infection in patients with advanced liver disease. Gastroenterology 2015;149:649-59.
31. Agarwal K, Castells L, Müllhaupt B, Rosenberg WMC, McNabb B, et al. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-
infected liver transplant recipients. J Hepatol 2018;69:603-7.
32. Fontana RJ, Brown RS Jr, Moreno-Zamora A, Prieto M, Joshi S, et al. Daclatasvir combined with sofosbuvir or simeprevir in liver
transplant recipients with severe recurrent hepatitis C infection. Liver Transpl 2016;22:446-58.
33. O’Leary JG, Fontana RJ, Brown K, Burton JR Jr, Firpi-Morell R, et al. Efficacy and safety of simeprevir and sofosbuvir with and
without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study.
Transpl Int 2017;30:196-208.
34. Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced
patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase
3 study. Lancet 2015;386:1537-45.
35. Gane Ed, Lawitz E, Pugatch D, Papatheodoridis G, Bräu N, et al. EXPEDITION-4: efficacy and safety of glecaprevir/pibrentasvir
(ABT-493/ABT-530) in patients with renal impairment and chronic hepatitis C virus genotype 1-6 infection. Hepatology
2016;64:1125A.
36. Colombo M, Aghemo A, Liu H, Zhang J, Dvory-Sobol H, et al. Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney
transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial. Ann Intern Med 2017;166:109-17.
37. Sawinski D, Kaur N, Ajeti A, Trofe-Clark J, Lim M, et al. Successful treatment of hepatitis C in renal transplant recipients with direct-
acting antiviral agents. Am J Transplant 2016;16:1588-95.
38. Goetsch MR, Tamhane A, Varshney M, Kapil A, Overton ET, et al. Direct-acting antivirals in kidney transplant patients: successful
hepatitis C treatment and short-term reduction in urinary protein/creatinine ratios. Pathog Immun. 2017;2:366-75.
39. Balistreri WF, Murray KF, Rosenthal P, Bansal S, Lin CH, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents
12-17 years old with hepatitis C virus genotype 1 infection. Hepatology 2017;66:371-8.
40. Wirth S, Rosenthal P, Gonzalez-Peralta RP, Jonas MM, Balistreri WF, et al. Sofosbuvir and ribavirin in adolescents 12-17 years old
with hepatitis C virus genotype 2 or 3 infection. Hepatology 2017;66:1102-10.
41. CROI. Retreatment of HCV/HIV-coinfected patients who failed 12 weeks of LDV/SOF. Available from: www.croiconference.org/
sessions/retreatment-hcvhiv-coinfected-patients-who-failed-12-weeks-ldvsof. [Last accessed on 28 Nov 2018]
42. EASL. Sofosbuvir/velpatasvir in combination with ribavirin for 24 weeks is effective retreatment for patients who failed prior NS5A